Yi Han
About Yi Han
Yi Han serves as the Vice President and Head of Strategy & Portfolio Management at AffaMed Therapeutics, a position he has held since 2020. He has a strong academic background in pharmacy and clinical pharmacology, with experience in various leadership roles at major pharmaceutical companies.
Work at AffaMed Therapeutics
Yi Han serves as the Vice President and Head of Strategy & Portfolio Management at AffaMed Therapeutics. He has held this position since 2020, contributing to the company's strategic initiatives and portfolio management efforts. His role involves overseeing the development and execution of strategies that align with the company's objectives in the biopharmaceutical sector. AffaMed Therapeutics operates in Shanghai, China, where Yi Han has been instrumental in driving the company's growth and innovation.
Education and Expertise
Yi Han has a robust educational background in pharmacy and clinical pharmacology. He completed his PhD in Pharmacy at the National University of Singapore from 2002 to 2007. He furthered his studies at the Department of Clinical Pharmacology at the University of Helsinki, where he achieved a Postdoctoral position from 2008 to 2009. Additionally, he holds a Project Management Professional (PMP) certification from PMI, enhancing his expertise in project management within the pharmaceutical industry.
Background in Pharmaceutical Industry
Yi Han has extensive experience in the pharmaceutical industry, having worked in various prominent roles. He was a Clinical Pharmacology Manager at AstraZeneca for six months in 2015-2016. Prior to that, he spent five years at Novartis as an Investigator in Clinical PKPD from 2010 to 2015. His experience also includes a three-year tenure at Pfizer as Head of Portfolio and Project Management in Development China from 2016 to 2019. This diverse background has equipped him with a comprehensive understanding of clinical development and project management.
Professional Experience Timeline
Yi Han's professional journey spans multiple key positions in the pharmaceutical sector. After completing his PhD, he worked at Novartis from 2010 to 2015. He then transitioned to AstraZeneca for a brief period in 2015-2016. Following this, he joined Pfizer, where he worked until 2019. In 2020, he took on his current role at AffaMed Therapeutics. This timeline reflects his progressive career in clinical pharmacology and strategic management.